Biogen asks why Ireland won’t fund new spinal muscular atrophy drug

Biogen is also urgently calling on the HSE to reform the appraisal process for orphan medicines to treat rare diseases, arguing that there is a need for a greater degree of flexibility for these assessments

Susan Mitchell

Deputy Editor and Health Editor @susmitchellsbp
22nd July, 2018

Biogen Ireland has called on Minister for Health Simon Harris to explain why Ireland joined an EU pharma partnership yet remains the only country in the partnership refusing to fund Biogen’s drug.

Ireland joined the partnership, called BeNeLuxA (Belgium, Netherlands, Luxembourg, Austria) in June. It aims to jointly negotiate pharmaceutical deals.

The partnership recently reached its first collective pricing agreement on Spinraza, which is used to treat Spinal Muscular Atrophy (SMA) – a...

Subscribe from just €1 for the first month!


What's Included

With any subscription you will have access to

  • 971569B3-2C5E-4C45-B798-CEADE16987A8

    Unlimited multi-device access to our iPad, iPhone and Android Apps

  • 099C8662-C57C-42F2-9426-F2F90DF17C8F

    Unlimited access to our eReader library

  • 198AE43B-B9CF-4892-8769-D63C2104BA08

    Exclusive daily insight and opinion seven days a week

  • D8F37B78-25E4-4E4A-A376-4F5789B1564A

    Create alerts to never miss a subject that matters to you

  • B15F2521-37CD-4E02-B898-730A20D39F7F

    Get access to exclusive offers for subscribers on gifts and experiences

  • A564FE02-1AB8-4579-AF9D-BA32A2E5ACA7

    Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine

Share this post

Related Stories

Donnelly ‘may seek legal advice’ before publishing first phase of Grace report

State paid GPs 40 per cent more during pandemic

Rosemary MacCabe: an essay

Tony O’Brien: Our kite-flying politicians haven’t yet given health workers a red cent